(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller ...

AbbVie (NYSE:ABBV) just scored a big win for its next-generation arthritis drug. The company said Monday that Rinvoq ...

The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...

The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...

The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

AbbVie (ABBV) on Monday said that the U.S. Food and Drug Administration has approved an update to the indication statement for its drug Rinvoq for the treatment of adults with moderately to severely ...

AbbVie said its Rinvoq showed superiority over the company’s previous bestselling drug Humira in a head-to-head trial. Results showed that 43% of patients compared to 22% of patients on Humira ...

As in any month, September was eventful for AbbVie. In addition to news about its usual activities, it also scored big with ...

AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...